These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27457423)

  • 1. Fusion of an albumin-binding domain extends the half-life of immunotoxins.
    Guo R; Guo W; Cao L; Liu H; Liu J; Xu H; Huang W; Wang F; Hong Z
    Int J Pharm; 2016 Sep; 511(1):538-549. PubMed ID: 27457423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.
    Liu H; Seijsing J; Frejd FY; Tolmachev V; Gräslund T
    Int J Oncol; 2015 Aug; 47(2):601-9. PubMed ID: 26046132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bispecific immunotoxin (IHPP) with a long half-life targeting HER2 and PDGFRβ exhibited improved efficacy against HER2-positive tumors in a mouse xenograft model.
    Guo R; Yang Y; Zhang D; Du J; Zhu X; Liu Y; Yang F; Lin J
    Int J Pharm; 2021 Jan; 592():120037. PubMed ID: 33161038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 5. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
    Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
    Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
    Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.
    Andersen JT; Pehrson R; Tolmachev V; Daba MB; Abrahmsén L; Ekblad C
    J Biol Chem; 2011 Feb; 286(7):5234-41. PubMed ID: 21138843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Serum Albumin and HER2-Binding Affibody Fusion Proteins for Targeted Delivery of Fatty Acid-Modified Molecules and Therapy.
    Dong D; Xia G; Li Z; Li Z
    Mol Pharm; 2016 Oct; 13(10):3370-3380. PubMed ID: 27546214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity.
    Guo R; Cao L; Guo W; Liu H; Xu H; Fang Q; Hong Z
    Biochem Biophys Res Commun; 2016 Jun; 475(1):93-9. PubMed ID: 27178207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
    Bera TK; Pastan I
    Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.
    Meyer S; Nederend M; Jansen JH; Reiding KR; Jacobino SR; Meeldijk J; Bovenschen N; Wuhrer M; Valerius T; Ubink R; Boross P; Rouwendal G; Leusen JH
    MAbs; 2016; 8(1):87-98. PubMed ID: 26466856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin.
    Shinohara H; Morita S; Kawai M; Miyamoto A; Sonoda T; Pastan I; Tanigawa N
    J Surg Res; 2002 Feb; 102(2):169-77. PubMed ID: 11796015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin.
    Altai M; Liu H; Orlova A; Tolmachev V; Gräslund T
    Int J Oncol; 2016 Sep; 49(3):1185-94. PubMed ID: 27573289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
    Griffin T; Raso V
    Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
    Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
    Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins.
    Cantante C; Lourenço S; Morais M; Leandro J; Gano L; Silva N; Leandro P; Serrano M; Henriques AO; Andre A; Cunha-Santos C; Fontes C; Correia JDG; Aires-da-Silva F; Goncalves J
    J Biotechnol; 2017 Jul; 253():23-33. PubMed ID: 28549690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
    Zhang J; Bodenko V; Larkina M; Bezverkhniaia E; Xu T; Liao Y; Abouzayed A; Plotnikov E; Tretyakova M; Yuldasheva F; Belousov MV; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
    J Control Release; 2024 Jun; 370():468-478. PubMed ID: 38697314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.